

Efficacies of treatments for anti-NMDA receptor encephalitis

Hsiuying Wang¹

¹*Institute of Statistics, National Chiao Tung University, Hsinchu 30010, Taiwan*

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Methods
4. Results
5. Discussion
6. Conclusion
7. Acknowledgments
8. References

1. ABSTRACT

Treatments for anti-N-methyl-D-aspartate (NMDA) receptor encephalitis include immunotherapy with steroids, intravenous immunoglobulin, plasma exchange, or plasmapheresis as first-line treatments, immunotherapy with rituximab or cyclophosphamide as second-line treatments, and tumor removal. In this systematic review, we evaluated previous studies and examined the association between certain microRNAs and anti-NMDA receptor encephalitis to investigate the performance of different treatment combinations. The efficacies of different combinations of treatments classified into the following four categories were compared: (I) intravenous immunoglobulin administration, (II) plasmapheresis or plasma exchange, (III) treatment with rituximab or cyclophosphamide and (IV) tumor removal. Statistical analyses showed that treatment combinations including at least two of these categories resulted in higher efficacy rates than treatment with a single form of therapy. These findings suggest that if a patient is not recovering, converting to other therapies is more likely to result in early recovery than continuing on the original therapy.

2. INTRODUCTION

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis is an acute form of encephalitis that has recently been reported as an autoimmune disorder exhibiting a well-defined set of clinical features. This form of encephalitis was described and defined by Dalmau *et al* (1). Thereafter, new cases of anti-NMDA receptor encephalitis have been identified around the world, and many cases have been reported in the literature. A diagnosis of anti-NMDA receptor encephalitis requires the detection of anti-NMDA antibodies in the blood or spinal fluid of an individual in association with symptoms consistent with this disease. Currently, this disease

can be diagnosed using a test that was developed at the University of Pennsylvania and that is available worldwide. However, anti-NMDA receptor encephalitis is a rare disease, and patients with this disease may not be diagnosed early. In general, early diagnosis and aggressive treatment improve patient outcomes.

Most patients with anti-NMDA receptor encephalitis develop a multistage illness that progresses from initial psychiatric symptoms to memory disturbances, seizures, dyskinesia and catatonia. In addition to these symptoms, tumors have been detected in a proportion of anti-NMDA receptor encephalitis patients according to previous studies. Therefore, it has been suggested that these patients be screened for tumors.

Steroids, intravenous immunoglobulin (IVIG) or plasma exchange (or plasmapheresis) either alone or in combination constitute the first-line immunotherapies for anti-NMDA receptor encephalitis; rituximab or cyclophosphamide is administered alone or in combination as a second-line immunotherapy. It is suggested that identified tumors be resected from these patients. Most patients are initially treated with steroids. Because steroids are commonly initially administered to encephalitis patients and because their cost is low, we did not consider treatment with steroids in our comparison of treatments. In this study, we compared the effects of different combinations of therapies, including IVIG, plasma exchange (or plasmapheresis), rituximab (or cyclophosphamide) and tumor resection.

Although it has been reported that 79% of patients with anti-NMDA receptor encephalitis achieve a good outcome within 24 months of disease onset (2), some patients largely recover within approximately one year. Because an increasing number of anti-NMDA

receptor encephalitis cases are being diagnosed, it is important to identify the factors that may lead to early recovery. The choice of treatments may be a factor that promotes early recovery from anti-NMDA receptor encephalitis, and physicians can more easily control the selection of treatments than other factors, such as the overall health of a patient, which cannot be controlled directly by physicians. As a result, it is difficult for such factors to be of practical use in the development of strategies to promote early recovery from anti-NMDA receptor encephalitis. Therefore, in this study, we focused on comparing the response to treatments for anti-NMDA receptor encephalitis.

Regarding anti-NMDA receptor encephalitis, it has not been shown whether any particular treatment regimen is superior to another. Moreover, it is difficult to directly compare the effects of different treatments. The possible reasons why it is unknown whether any one set of treatments is more beneficial than another are that (i) no single treatment regimen is superior to the others or (ii) the treatment effects are confounded because each patient may receive different treatments. Therefore, in this study, we collected case reports that clearly described the therapies used to treat patients with anti-NMDA receptor encephalitis and then analyzed the differences in treatment between the patients who recovered early and those who did not. The results of this study showed that combinations of treatments including at least two therapy categories resulted in higher efficacy rates than treatments with a single form of therapy.

In addition to comparing these case reports, we reviewed a previous study of the relationship between the levels of microRNAs (miRNAs) and anti-NMDA receptor encephalitis. miRNAs are single-stranded, non-coding RNAs consisting of 22–24 nucleotides that play important roles in genome expression and that are involved in several biological processes (3-5). Among the several hundred miRNAs expressed in the human brain, let-7 is one of the most abundant (6). Significant down-regulation of let-7a, let-7b, let-7d, and let-7f was demonstrated in anti-NMDA receptor encephalitis patients (7).

It has been revealed that let-7 is closely associated with human cancer and innate immune responses (8); it is often suggested that those with these diseases receive multiple forms of treatment. This recommendation coincides with the suggested therapeutic strategy for anti-NMDA receptor encephalitis, in which let-7 is significantly down-regulated.

3. METHODS

We searched for case reports in the literature and evaluated treatment combinations with respect to the endpoint of complete recovery within approximately one year. We reviewed case reports of 94 anti-NMDA

receptor encephalitis patients, including 18 male patients and 76 female patients. The age of the patients ranged between 8 months and 84 years. The treatment regimens administered to these patients were classified into 4 categories: IVIG; plasma exchange or plasmapheresis; rituximab or cyclophosphamide; and tumor resection. Any treatment regimen that included different categories was considered as a treatment combination.

The treatments received by each patient are listed in Table 1. Although 79% of anti-NMDA receptor encephalitis patients completely recovered within 2 years (2), many cases achieved good recovery within approximately one year of symptom onset. To compare the efficacies of different treatment combinations and to identify treatment combinations that may shorten the recovery time, we set one year as a threshold for the recovery time. For each treatment combination, we calculated the efficacy rate as the ratio of the number of patients with a recovery time within approximately one year to the total number of patients who received the given treatment combination. A higher efficacy rate of a given treatment combination indicates that this treatment combination is more likely to result in recovery within one year of symptom onset.

Table 1 presents gender, age, treatments administered, the corresponding references, and the recovery time (within or beyond approximately one year) for the 94 patients included in our analysis. In three cases presented in Table 1, the treatment of the patients requires explanation. Systemic hypotension occurred as a complication during a second plasma exchange session in the patient described in reference (9). Therefore, we recorded only the IVIG treatment administered to this patient. The patient described in (10) began rituximab therapy at 13 months after initial discharge. Because the efficacy rate was computed only for recovery times within approximately one year, we considered only the IVIG treatment that was administered to this patient. Tumor resection was performed on the patient described in (11) more than one year after symptom onset; therefore, we did not consider this treatment in certain analyses.

4. RESULTS

We used the cases listed in Table 1 as a random sample to compare the efficacy rates of different treatment combinations. We separated the treatments into 4 categories, as shown in Table 1: (I) IVIG administration, (II) plasma exchange or plasmapheresis, (III) treatment with rituximab or cyclophosphamide and (IV) tumor resection. We applied a logistic regression model to explore the relationship between the efficacy rate and each form of treatment.

Let X_i , $i = 1, \dots, 4$ denote the indicator function of receiving a treatment in the i th category. That is,

Table 1. Treatment of ninety-four anti-NMDA receptor encephalitis patients

Gender	Age (years)	Complete recovery within approximately one year	Treatment category				Reference
			I	II	III	IV	
M	45			v	v		(14)
F	30		v	v	v		(15)
F	19	v	v	v		v	(16)
F	23	v	v	v	v	v	(17)
F	25						(18)
F	9						(19)
F	11	v	v		v		(20)
F	17	v	v			v	(21)
F	9	v	v		v		(22)
F	17		v	v	v		(23)
F	3	v	v		v		(24)
M	16		v				(24)
F	35	v	v		v	v	(25)
M	20 months		v		v		(26)
F	26	v				v	(27)
F	23		v				(9)
F	3	v	v				(28)
F	18	v		v		v	(29)
F	16	v	v	v		v	(30)
F	20 months	v	v		v		(31)
M	30	v	v	v			(32)
M	2		v				(10)
F	9	v	v	v	v	v	(33)
M	8 months		v				(34)
F	4	v	v				(35)
M	50	v					(36)
M	8		v				(37)
F	16		v				(38)
M	35				v		(39)
F	3 years 2 months		v	v	v		(40)
F	9	v	v		v		(41)
F	14	v	v				(42)
F	7		v	v	v		(43)
F	8		v				(43)
M	73	v					(44)
F	65			v	v		(45)
M	66	v	v	v	v		(46)
F	4	v	v				(47)

(Cond...)

Table 1. (Continued...)

Gender	Age (years)	Complete recovery within approximately one year	Treatment category				Reference
			I	II	III	IV	
M	8	v	v		v		(47)
F	14		v				(48)
F	5	v	v				(49)
F	21	v	v	v		v	(50)
F	14	v	v		v	v	(51)
F	25	v	v	v			(52)
F	26	v	v				(53)
F	15	v	v		v		(54)
F	15	v	v		v		(54)
F	17	v	v	v	v		(54)
F	31	v		v	v		(55)
M	6	v	v				(56)
F	4		v				(56)
M	17	v	v	v			(57)
F	24	v	v	v		v	(58)
F	21	v	v			v	(59)
F	14	v	v	v	v		(60)
F	29	v	v		v	v	(61)
F	34	v	v	v	v	v	(62)
F	42	v					(63)
F	38	v					(63)
M	13.5		v				(64)
F	29	v		v	v		(65)
M	68						(66)
F	17	v		v		v	(67)
F	41	v					(68)
F	70	v			v		(69)
F	19		v				(70)
F	33	v		v		v	(71)
F	27 months	v	v		v		(72)
F	27 months	v	v	v	v		(72)
F	27	v	v			v	(73)
F	11	v		v		v	(74)
F	20	v				v	(75)
F	21	v	v	v		v	(76)
F	42		v			v	(77)
M	18		v		v		(78)
F	15	v	v			v	(79)

(Cond...)

Table 1. (Continued...)

Gender	Age (years)	Complete recovery within approximately one year	Treatment category				Reference
			I	II	III	IV	
F	21		v	v		v	(80)
F	84		v	v			(80)
M	38		v	v	v		(80)
F	65					v	(81)
F	19	v		v	v	v	(82)
F	21	v	v			v	(83)
F	3 years 9 months	v	v				(84)
F	21						(11)
F	15	v	v			v	(85)
F	20	v	v			v	(86)
F	17		v				(87)
F	33		v				(87)
F	5	v					(88)
F	25	v	v			v	(89)
F	26	v	v			v	(90)
F	17	v				v	(91)
F	28	v					(92)
F	18	v		v		v	(93)
Total		63	67	32	33	32	

(I) IVIG administration; (II) plasma exchange or plasmapheresis; (III) treatment with rituximab or cyclophosphamide; (IV) tumor resection

Table 2. The effect of each treatment

	Estimated value	p-value
α	0.1485	0.7665
β_1 (treatment in category (I))	-0.2381	0.6563
β_2 (treatment in category (II))	-0.2602	0.6489
β_3 (treatment in category (III))	0.7048	0.2021
β_4 (treatment in category (IV))	2.2857	0.0011 (<0.05)

let $X = 0$ or 1 indicate that a patient did not receive or did receive a treatment in the t th category, respectively. Consider the logistic regression model

$$\log \frac{p}{1-p} = \alpha + \beta_1 x_1 + \beta_2 x_2 + \beta_3 x_3 + \beta_4 x_4 \quad (1),$$

where β_i , $i = 1, \dots, 4$ and α are the coefficients of the regression model and p is the proportion of patients with a recovery time within approximately one year, conditional on X_i . We applied model (1) to the data for the 94 patients analyzed in this study. The estimated values for α and β_i and their corresponding p-values are

presented in Table 2. The results showed that the effects of each form of treatment, with the exception of tumor resection, were not significant.

Although the effects of the individual treatments in categories (I)-(III) were not significant, our primary interest was to identify treatment combinations that result in significantly shortened recovery, as many patients receive more than one form of treatment. Because the sample sizes for some treatment combinations were not sufficiently large to draw firm conclusions, we instead focused on the relationship between the efficacy rate and the number of categories of treatments included in a treatment combination. The efficacy rates of the 5 possible treatment categories included in a treatment combination, ranging from no treatment to all 4 treatment categories, are presented in Table 3. A comparison of these rates revealed that the efficacy rates of treatment combinations including more than 1 form of treatment were higher than those including only a single form of treatment. However, most likely because of the insufficient sample sizes for certain treatment combinations, for example, a sample size of 3 for the treatment combination consisting of all 4




Figure 1. Histogram showing the number of patients receiving each number of treatment categories according to the recovery time.

Table 3. Number of patients and efficacy rates for each number of treatment categories included in the therapy

Number of categories of treatments administered	0	1	2	3	4	Total
Complete recovery within approximately one year	7	12	28	13	3	63
Complete recovery beyond one year	4	15	6	6	0	31
Total	11	27	34	19	3	94
Efficacy rate	0.636	0.444	0.824	0.684	1	0.670

Table 4. Number of patients and efficacy rates for therapies including one or no treatment categories and for therapies including least two treatment categories

	One or no treatment categories	At least two treatment categories	Total
Complete recovery within approximately one year	19	44	63
Complete recovery beyond one year	19	12	31
Total	38	56	94
Efficacy rate	0.5	0.786	0.67
95% CI of efficacy rate	(0.34, 0.66)	(0.68, 0.89)	(0.57, 0.77)

forms of treatment, no statistically significant difference was observed between the 5 possible treatment categories. Figure 1 shows a histogram of the treatment combinations including different numbers of treatment categories according to the recovery time.

To determine the relationship between efficacy rates and treatment combinations, we analyzed the data using additional logistic regression models. Significant results were found using the logistic regression model

$$\log \frac{p}{1-p} = a s \quad (2),$$

where, $s=0, 1$ denotes that the treatment included no greater than 1 category of treatment or more than 1 category of treatment, respectively and where p is the proportion of patients experiencing recovery within approximately one year, conditional on. That is, $s=0$ represents the treatment combinations consisting of a single form of treatment, and $s=1$ represents the treatment combinations consisting of at least two forms of treatment.

The estimated value of α for model (2) was $\hat{a} = 1.2993$, with a p-value of 0.0047. This result showed that the efficacy rates between a single form of treatment and treatment combinations were significantly different. Table 4 shows that the efficacy rates were 0.5 for receiving a single form or no forms of treatment and 0.786 for receiving at least 2 forms of treatment.

Additional statistical analyses were performed to validate this conclusion. Using a method that compares two binomial proportions, we tested whether the efficacy rate of receiving a single form of treatment was equivalent to the efficacy rate of receiving at least 2 treatments; we obtained a p-value of 0.003, which resulted in the rejection of the null hypothesis considering a type 1 error threshold of 0.05. Therefore, we concluded that therapies including at least 2 forms of treatment had a higher efficacy rate than therapy using only one or no forms of treatment. Additionally, the odds ratio was, this result showed that patients who received at least 2 forms of treatment were much more likely to recover within one year than patients who received only one or no forms of

treatment. We also calculated 95% confidence intervals for both efficacy rates; these intervals were (0.34, 0.66) for the efficacy rate of receiving a single or no forms of treatment and (0.68, 0.89) for the efficacy rate of receiving at least 2 forms of treatment. The upper bound of the formal interval, 0.66, is smaller than the lower bound of the latter interval, 0.68.

The efficacy rates for the male and female patients were 0.389 and 0.727, respectively. Using a method that compares two binomial proportions, we tested whether the efficacy rates for males and females were equivalent; we obtained a p-value of 0.007, which resulted in a rejection of the null hypothesis considering a type 1 error-threshold of 0.05. Thus, we concluded that the efficacy rates were higher in the female patients than in the male patients.

The numbers of patients who received treatments in each of the 4 categories are presented in Table 1. Next, we ranked the probabilities that each treatment category would be used. We considered this analysis as a ranking of the responses to a multiple-response question because each patient could choose any of the treatments, with the exception of tumor resection. Thus, we applied the ranking code “rank.wald” in the R package RankResponse (12) to rank these treatments (12, 13). The ranks of the 4 treatment categories were found to be 1, 4, 4, and 4, corresponding to the first, second, third and fourth categories, respectively. These data showed that IVIG was administered the most frequently.

5. DISCUSSION

The results of this study showed that different treatment combinations result in significantly different outcomes. However, this study contains some limitations. One limitation is that the data analyzed in this study were collected from case reports. Additional factors such as treatment delays and disease severity are known to influence patient outcomes, and we cannot determine whether any of these additional factors varied among the patients analyzed in this study. However, because anti-NMDA receptor encephalitis is a rare disease, even in the context of a carefully designed experiment, it would be difficult to control for the influences of these factors on patient outcomes. Therefore, we believe that any significant results obtained by analyzing different treatment strategies according to case reports can provide useful information about the efficacy of therapies for anti-NMDA receptor encephalitis.

In addition, treatment decisions for the population studied were based on several factors, including treatment decisions by patients, the presence or absence of a tumor, and physician- and institution-specific factors. Potential side effects and the risk of recurrence are additional important factors in treatment

decisions. Therefore, we do not recommend any specific treatment based on the results of this study.

6. CONCLUSION

Anti-NMDA receptor encephalitis is an acute encephalitis that presents with psychiatric symptoms in association with other symptoms characteristic of encephalitis. Low-grade fever, headache, common cold-like symptoms, and gastroenteritis are prodromal symptoms that are observed in most cases. A portion of anti-NMDA receptor encephalitis patients who are diagnosed early and treated properly have a good prognosis. The recovery time of the cases experiencing complete recovery ranges from several months to several years. In this study, we compared the cases with a recovery time within approximately one year to the cases with a recovery time of greater than one year. The results revealed that patients who received more than one form of treatment had a significantly shorter recovery time than those who received a single form of treatment. These results suggest that if a patient is not recovering, converting to other therapies is more likely to result in early recovery than continuing on the original therapy. In addition, after steroids, IVIG was most frequently administered to patients with anti-NMDA receptor encephalitis.

7. ACKNOWLEDGMENTS

This study was supported by the Ministry of Science and Technology of Taiwan (103-2118-M-009-001-MY) and was particularly supported by National Chiao Tung University, Taiwan.

8. REFERENCES

1. J. Dalmau, E. Tuzun, H. Y. Wu, J. Masjuan, J. E. Rossi, A. Voloschin, J. M. Baehring, H. Shimazaki, R. Koide, D. King, W. Mason, L. H. Sansing, M. A. Dichter, M. R. Rosenfeld and D. R. Lynch: Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Ann Neurol*, 61(1), 25-36 (2007)
DOI: 10.1002/ana.21050
2. M. J. Titulaer, L. McCracken, I. Gabilondo, T. Armangue, C. Glaser, T. Iizuka, L. S. Honig, S. M. Benseler, I. Kawachi, E. Martinez-Hernandez, E. Aguilar, N. Gresa-Arribas, N. Ryan-Flanagan, A. Torrents, A. Saiz, M. R. Rosenfeld, R. Balice-Gordon, F. Graus and J. Dalmau: Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. *Lancet Neurol*, 12(2), 157-65 (2013)
DOI: 10.1016/S1474-4422(12)70310-1

3. H. Wang and W. H. Li: Increasing MicroRNA target prediction confidence by the relative R(2) method. *J Theor Biol*, 259(4), 793-8 (2009)
DOI: 10.1016/j.jtbi.2009.05.007
4. W. J. Hsieh, F. M. Lin, H. D. Huang and H. Wang: Investigating microRNA-target interaction-supported tissues in human cancer tissues based on miRNA and target gene expression profiling. *PLoS One*, 9(4), e95697 (2014)
DOI: 10.1371/journal.pone.0095697
5. H. Wang: Predicting cancer-related MiRNAs using expression profiles in tumor tissue. *Curr Pharm Biotechnol*, 15(5), 438-44 (2014)
DOI: 10.2174/1389201015666140519121255
6. S. M. Lehmann, C. Kruger, B. Park, K. Derkow, K. Rosenberger, J. Baumgart, T. Trimbuch, G. Eom, M. Hinz, D. Kaul, P. Habel, R. Kalin, E. Franzoni, A. Rybak, D. Nguyen, R. Veh, O. Ninnemann, O. Peters, R. Nitsch, F. L. Heppner, D. Golenbock, E. Schott, H. L. Ploegh, F. G. Wulczyn and S. Lehnardt: An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. *Nat Neurosci*, 15(6), 827-35 (2012)
DOI: 10.1038/nn.3113
7. J. Zhang, X. Xu, S. Zhao, Z. Gong, P. Liu, W. Guan, X. He, T. Wang, T. Peng, J. Teng and Y. Jia: The Expression and Significance of the Plasma Let-7 Family in Anti-N-methyl-D-aspartate Receptor Encephalitis. *J Mol Neurosci* (2015)
8. G. A. Calin, C. Sevignani, C. D. Dumitru, T. Hyslop, E. Noch, S. Yendamuri, M. Shimizu, S. Rattan, F. Bullrich, M. Negrini and C. M. Croce: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proc Natl Acad Sci U S A*, 101(9), 2999-3004 (2004)
DOI: 10.1073/pnas.0307323101
9. M. Kurian, P. H. Lalive, J. O. Dalmau and J. Horvath: Opsoclonus-myoclonus syndrome in anti-N-methyl-D-aspartate receptor encephalitis. *Arch Neurol*, 67(1), 118-21 (2010)
DOI: 10.1001/archneurol.2009.299
10. Y. Hachiya, A. Uruha, E. Kasai-Yoshida, K. Shimoda, I. Satoh-Shirai, S. Kumada, E. Kurihara, K. Suzuki, A. Ohba, S. Hamano and H. Sakuma: Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. *J Neuroimmunol*, 265(1-2), 128-30 (2013)
11. J. W. Lo, E. Y. Leung, B. L. Ng, M. H. Fu, K. K. Yip, R. T. Chan and C. M. Chang: Anti-N-methyl-D-aspartate receptor encephalitis in a young woman with an ovarian tumour. *Hong Kong Med J*, 16(4), 313-6 (2010)
12. H. Wang and Y. C. Lin: RankResponse: Ranking Responses in a Single Response Question or a Multiple Response Question. *R package version 3.1.1*. (2014)
13. H. Wang: Ranking responses in multiple-choice questions. *Journal of Applied Statistics*, 35(4), 465-474 (2008)
DOI: 10.1080/02664760801924533
14. C. W. Beatty, C. J. Creutzfeldt, A. P. Davis, Z. Hoffer and S. P. Khot: The diagnostic conundrum and treatment dilemma of a patient with a rapidly progressive encephalopathy. *Neurohospitalist*, 4(1), 34-41 (2014)
DOI: 10.1177/1941874413496792
15. A. Thomas, P. Rauschkolb, N. Gresa-Arribas, A. Schned, J. O. Dalmau and C. E. Fadul: Anti-N-methyl-D-aspartate receptor encephalitis: a patient with refractory illness after 25 months of intensive immunotherapy. *JAMA Neurol*, 70(12), 1566-8 (2013)
DOI: 10.1001/jamaneurol.2013.3205
16. O. Sanmaneechai, J. L. Song, N. Nevadunsky, S. L. Moshe and P. J. Overby: Anti-N-methyl-d-aspartate encephalitis with ovarian cystadenofibroma. *Pediatr Neurol*, 48(3), 232-5 (2013)
DOI: 10.1016/j.pediatrneurol.2012.10.013
17. S. U. Jantzen, S. Ferrea, C. Wach, K. Quasthoff, S. Illes, D. Scherfeld, H. P. Hartung, R. J. Seitz and M. Dihne: *In vitro* neuronal network activity in NMDA receptor encephalitis. *BMC Neurosci*, 14, 17 (2013)
18. H. C. Hansen, C. Klingbeil, J. Dalmau, W. Li, B. Weissbrich and K. P. Wandinger: Persistent intrathecal antibody synthesis 15 years after recovering from anti-N-methyl-D-aspartate receptor encephalitis. *JAMA Neurol*, 70(1), 117-9 (2013)
DOI: 10.1001/jamaneurol.2013.585
19. W. K. Van Putten, S. Hachimi-Idrissi, A. Jansen, V. Van Gorp and L. Huyghens:

- Uncommon cause of psychotic behavior in a 9-year-old girl: a case report. *Case Rep Med*, 2012, 358520 (2012)
20. P. Maggina, M. Mavrikou, S. Karagianni, C. L. Skevaki, A. Triantafyllidou, C. Voudris, E. Katsarou, L. Stamogiannou and S. Mastroyianni: Anti-N-methyl-D-aspartate receptor encephalitis presenting with acute psychosis in a preteenage girl: a case report. *J Med Case Rep*, 6, 224 (2012)
21. C. L. Xu, L. Liu, W. Q. Zhao, J. M. Li, R. J. Wang, S. H. Wang, D. X. Wang, M. Y. Liu, S. S. Qiao and J. W. Wang: Anti-N-methyl-D-aspartate receptor encephalitis with serum anti-thyroid antibodies and IgM antibodies against Epstein-Barr virus viral capsid antigen: a case report and one year follow-up. *BMC Neurol*, 11, 149 (2011)
22. E. M. Goldberg, K. S. Taub, S. K. Kessler and N. S. Abend: Anti-NMDA receptor encephalitis presenting with focal non-convulsive status epilepticus in a child. *Neuropediatrics*, 42(5), 188-90 (2011)
DOI: 10.1055/s-0031-1295408
23. A. Consoli, K. Ronen, I. An-Gourfinkel, M. Barbeau, D. Marra, N. Costedoat-Chalumeau, D. Montefiore, P. Maksud, O. Bonnot, A. Didelot, Z. Amoura, M. Vidailhet and D. Cohen: Malignant catatonia due to anti-NMDA-receptor encephalitis in a 17-year-old girl: case report. *Child Adolesc Psychiatry Ment Health*, 5(1), 15 (2011)
DOI: 10.1186/1753-2000-5-15
24. N. Luca, T. Daengsuwan, J. Dalmau, K. Jones, G. deVeber, J. Kobayashi, R. M. Laxer and S. M. Benseler: Anti-N-methyl-D-aspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. *Arthritis Rheum*, 63(8), 2516-22 (2011)
DOI: 10.1002/art.30437
25. N. Johnson, C. Henry, A. J. Fessler and J. Dalmau: Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. *Neurology*, 75(16), 1480-2 (2010)
DOI: 10.1212/WNL.0b013e3181f8831a
26. L. C. Wong-Kisiel, T. Ji, D. L. Renaud, S. Kotagal, M. C. Patterson, J. Dalmau and K. J. Mack: Response to immunotherapy in a 20-month-old boy with anti-NMDA receptor encephalitis. *Neurology*, 74(19), 1550-1 (2010)
DOI: 10.1212/WNL.0b013e3181dd41a1
27. S. Ferioli, J. Dalmau, C. A. Kobet, Q. J. Zhai, J. P. Broderick and A. J. Espay: Anti-N-methyl-D-aspartate receptor encephalitis: characteristic behavioral and movement disorder. *Arch Neurol*, 67(2), 250-1 (2010)
DOI: 10.1001/archneurol.2009.317
28. N. R. Florance, R. L. Davis, C. Lam, C. Szperka, L. Zhou, S. Ahmad, C. J. Campen, H. Moss, N. Peter, A. J. Gleichman, C. A. Glaser, D. R. Lynch, M. R. Rosenfeld and J. Dalmau: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. *Ann Neurol*, 66(1), 11-8 (2009)
DOI: 10.1002/ana.21756
29. M. Seki, S. Suzuki, T. Iizuka, T. Shimizu, Y. Nihei, N. Suzuki and J. Dalmau: Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. *J Neurol Neurosurg Psychiatry*, 79(3), 324-6 (2008)
DOI: 10.1136/jnnp.2007.136473
30. M. Appu and M. Noetzel: Clinically significant response to zolpidem in disorders of consciousness secondary to anti-N-methyl-D-aspartate receptor encephalitis in a teenager: a case report. *Pediatr Neurol*, 50(3), 262-4 (2014)
DOI: 10.1016/j.pediatrneurol.2013.11.001
31. E. M. Goldberg, M. Titulaer, P. M. de Blank, A. Sievert and N. Ryan: Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. *Pediatr Neurol*, 50(2), 181-4 (2014)
DOI: 10.1016/j.pediatrneurol.2013.10.002
32. I. B. Marques, R. Teotonio, C. Cunha, C. Bento and F. Sales: Anti-NMDA receptor encephalitis presenting with total insomnia--a case report. *J Neurol Sci*, 336(1-2), 276-80 (2014)
33. S. Nijmeijer, S. Bontemps, L. Naeije and J. Coutinho: Anti-N-methyl-D-aspartate receptor encephalitis in a pre-teenage girl: a case report. *Eur J Pediatr*, 173(5), 681-3 (2014)
DOI: 10.1007/s00431-013-2042-3
34. V. Cantarin-Extremiera, A. Duat-Rodriguez, L. Gonzalez-Gutierrez-Solana, L. Lopez-Marin and T. Armangué: Clinical case of anti-N-methyl-D-aspartate receptor encephalitis in an 8-month-old patient with hyperkinetic movement disorder. *Pediatr Neurol*, 48(5), 400-2 (2013)
DOI: 10.1016/j.pediatrneurol.2012.12.032

35. L. Safadie and O. Dabbagh: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis in a young Lebanese girl. *J Child Neurol*, 28(10), 1222-5 (2013)
DOI: 10.1177/0883073812456085
36. H. Suzuki, M. Kitada, S. Ueno, K. Tanaka and S. Kusunoki: Anti-NMDAR encephalitis preceded by dura mater lesions. *Neurol Sci*, 34(6), 1021-2 (2013)
DOI: 10.1007/s10072-012-1169-8
37. S. Raha, P. Gadgil, C. Sankhla and V. Udani: Nonparaneoplastic anti-N-methyl-D-aspartate receptor encephalitis: a case series of four children. *Pediatr Neurol*, 46(4), 246-9 (2012)
DOI: 10.1016/j.pediatrneurol.2012.01.012
38. S. Lebon, C. Mayor-Dubois, I. Popea, C. Poloni, N. Salvadoray, A. Gumy and E. Roulet-Perez: Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder in an adolescent. *J Child Neurol*, 27(12), 1607-10 (2012)
DOI: 10.1177/0883073812438099
39. A. Takeda, H. Shimada, A. Tamura, M. Yasui, K. Yamamoto, K. Itoh, S. Ataka, S. Tanaka, M. Ohsawa, H. Hatsuta, M. Hirano, H. Sakamoto, S. Ueno, Y. Nakamura, T. Tsutada and T. Miki: A case of anti-N-methyl-d-aspartate receptor encephalitis with multiple sclerosis-like demyelinated lesions. *Mult Scler Relat Disord*, 3(3), 391-7 (2014)
DOI: 10.1016/j.msard.2013.09.005
40. Y. H. Guo, T. S. Kuan, P. C. Hsieh, W. C. Lien, C. K. Chang and Y. C. Lin: Rehabilitation for a child with recalcitrant anti-N-methyl-d-aspartate receptor encephalitis: case report and literature review. *Neuropsychiatr Dis Treat*, 10, 2263-7 (2014)
41. S. Kaur, M. Juneja, D. Mishra and S. Jain: Anti-N-methyl-D-aspartate receptor encephalitis: A case report and review of the literature. *J Pediatr Neurosci*, 9(2), 145-7 (2014)
DOI: 10.4103/1817-1745.139322
42. T. Y. Hung, N. H. Foo and M. C. Lai: Anti-N-methyl-d-aspartate receptor encephalitis. *Pediatr Neonatol*, 52(6), 361-4 (2011)
DOI: 10.1016/j.pedneo.2011.08.012
43. A. Salvucci, I. M. Devine, D. Hammond and R. D. Sheth: Pediatric anti-NMDA (N-methyl D-aspartate) receptor encephalitis. *Pediatr Neurol*, 50(5), 507-10 (2014)
DOI: 10.1016/j.pediatrneurol.2014.01.012
44. D. Aguiar de Sousa, P. P. Lobo, A. C. Caldas, M. Coelho and L. Albuquerque: Pure ataxia associated with N-methyl-D-aspartate receptor antibodies. *Parkinsonism Relat Disord*, 20(5), 568-9 (2014)
DOI: 10.1016/j.parkreldis.2014.02.015
45. O. Outteryck, G. Baille, J. Hodel, M. Giroux, A. Lacour, J. Honnorat, H. Zephir and P. Vermersch: Extensive myelitis associated with anti-NMDA receptor antibodies. *BMC Neurol*, 13, 211 (2013)
46. D. Di Capua, S. Garcia-Ptacek, M. E. Garcia-Garcia, B. Abarrategui, J. Porta-Etessam and I. Garcia-Morales: Extreme delta brush in a patient with anti-NMDAR encephalitis. *Epileptic Disord*, 15(4), 461-4 (2013)
47. S. Ramanathan, S. S. Mohammad, F. Brilot and R. C. Dale: Autoimmune encephalitis: recent updates and emerging challenges. *J Clin Neurosci*, 21(5), 722-30 (2014)
DOI: 10.1016/j.jocn.2013.07.017
48. M. Mirabelli-Badenier, R. Biancheri, G. Morana, S. Fornarino, L. Siri, M. E. Celle, E. Veneselli, A. Vincent, R. Gaggero and M. M. Mancardi: Anti-NMDAR encephalitis misdiagnosed as Hashimoto's encephalopathy. *Eur J Paediatr Neurol*, 18(1), 72-4 (2014)
DOI: 10.1016/j.ejpn.2013.07.002
49. M. L. Yau and E. L. Fung: Early consideration of anti-NMDAR encephalitis in unexplained encephalopathy. *Hong Kong Med J*, 19(4), 362-4 (2013)
DOI: 10.12809/hkmj133602
50. Y. Tsuyusaki, R. Sakakibara, M. Kishi, F. Tateno and T. Yoshida: Downbeat nystagmus as the initial manifestation of anti-NMDAR encephalitis. *Neurological Sciences*, 35(1), 125-126 (2014)
DOI: 10.1007/s10072-013-1511-9
51. J. E. Wilson, J. Shuster and C. Fuchs: Anti-NMDA receptor encephalitis in a 14-year-old female presenting as malignant catatonia: medical and psychiatric approach to treatment. *Psychosomatics*, 54(6), 585-9 (2013)
DOI: 10.1016/j.psym.2013.03.002
52. N. Dericioglu, A. Vural, P. Acar, N. Agayeva, V. Ismailova, A. Kurne, E. Saka, E. M. Arsava and M. A. Topcuoglu: Antiepileptic treatment for anti-NMDA receptor encephalitis: the need for video-EEG monitoring. *Epileptic Disord*, 15(2), 166-70 (2013)

53. R. Kumar, D. Gunaratne, S. Khan, K. Crawford, M. Cook and R. Tuck: Acute neuropsychiatric manifestations of anti-N-methyl-D-aspartate receptor encephalitis. *Australas Psychiatry*, 21(3), 279-80 (2013)
DOI: 10.1177/1039856213476122
54. M. M. Esseveld, E. H. van de Riet, L. Cuyper and J. N. Schievelde: Drawings during neuropsychiatric recovery from anti-NMDA receptor encephalitis. *Am J Psychiatry*, 170(1), 21-2 (2013)
DOI: 10.1176/appi.ajp.2012.12070965
55. H. E. Hinson, C. Takahashi, G. Altowaijri, I. J. Baguley and D. Bourdette: Anti-NMDA receptor encephalitis with paroxysmal sympathetic hyperactivity: an under-recognized association? *Clin Auton Res*, 23(2), 109-11 (2013)
56. R. C. Dale, S. Pillai and F. Brilot: Cerebrospinal fluid CD19(+) B-cell expansion in N-methyl-D-aspartate receptor encephalitis. *Dev Med Child Neurol*, 55(2), 191-3 (2013)
DOI: 10.1111/dmcn.12036
57. X. Finne Lenoir, C. Sindic, V. van Pesch, S. El Sankari, M. de Tourtchaninoff, R. Denays and P. Hantson: Anti-N-methyl-D-aspartate receptor encephalitis with favorable outcome despite prolonged status epilepticus. *Neurocrit Care*, 18(1), 89-92 (2013)
DOI: 10.1007/s12028-012-9788-8
58. A. Vural, E. M. Arsava, N. Dericioglu and M. A. Topcuoglu: Central Neurogenic Hyperventilation in Anti-NMDA Receptor Encephalitis. *Internal Medicine*, 51(19), 2789-2792 (2012)
DOI: 10.2169/internalmedicine.51.8215
59. H. Aoki, S. Morita, N. Miura, T. Tsuji, Y. Ohnuki, Y. Nakagawa, I. Yamamoto, H. Takahashi and S. Inokuchi: Early diagnosis of anti-N-methyl-D-aspartate receptor encephalitis in a young woman with psychiatric symptoms. *Tokai J Exp Clin Med*, 37(3), 89-93 (2012)
60. A. Mann, N. M. Machado, N. Liu, A. H. Mazin, K. Silver and K. I. Afzal: A Multidisciplinary Approach to the Treatment of Anti-NMDA-Receptor Antibody Encephalitis: A Case and Review of the Literature. *Journal of Neuropsychiatry and Clinical Neurosciences*, 24(2), 247-254 (2012)
DOI: 10.1176/appi.neuropsych.11070151
61. R. Salazar, E. James, M. Elsayed, P. Varelas, J. Bartscher, J. Corry and T. Abdelhak: Profuse sialorrhea in a case of anti N-methyl-D-aspartate receptor (NMDAR) encephalitis. *Clin Neurol Neurosurg*, 114(7), 1066-9 (2012)
DOI: 10.1016/j.clineuro.2012.02.011
62. J. L. Tanyi, E. B. Marsh, J. Dalmau and C. S. Chu: Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. *Acta Obstet Gynecol Scand*, 91(5), 630-4 (2012)
DOI: 10.1111/j.1600-0412.2011.01365.x
63. E. Tuzun, R. Turkoglu, S. M. Yumerhodzha, E. Erdag, M. Eraksoy and G. Akman-Demir: Anti-N-methyl-D-aspartate receptor encephalitis with minimal cortical impairment. *Neurological Sciences*, 34(1), 111-113 (2013)
DOI: 10.1007/s10072-012-0934-z
64. R. Shah, A. Veerapandian, S. Winchester, W. Gallentine and M. A. Mikati: Two Patients With an Anti-N-Methyl-D-Aspartate Receptor Antibody Syndrome-Like Presentation and Negative Results of Testing for Autoantibodies. *Pediatric Neurology*, 45(6), 412-416 (2011)
DOI: 10.1016/j.pediatrneurol.2011.09.012
65. A. Y. X. Yu and F. G. A. Moore: Paraneoplastic Encephalitis Presenting as Postpartum Psychosis. *Psychosomatics*, 52(6), 568-570 (2011)
DOI: 10.1016/j.psych.2011.01.043
66. A. Uruha, Y. Kitazawa, M. Kuroda, K. Tanaka and R. Koide: Anti-NMDAR encephalitis in small-cell lung cancer: A case report. *Clinical Neurology and Neurosurgery*, 114(3), 260-261 (2012)
DOI: 10.1016/j.clineuro.2011.10.015
67. A. Sameshima, T. Hidaka, T. Shima, A. Nakashima, T. Hasegawa and S. Saito: Anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian immature teratoma. *Journal of Obstetrics and Gynaecology Research*, 37(12), 1883-1886 (2011)
DOI: 10.1111/j.1447-0756.2011.01671.x
68. M. Lee, N. Lawn, D. Prentice and J. Chan: Anti-NMDA receptor encephalitis associated with ictal asystole. *Journal of Clinical Neuroscience*, 18(12), 1716-1718 (2011)
DOI: 10.1016/j.jocn.2011.03.024
69. H. Suzuki, M. Samukawa, M. Kitada, J. Ichihashi, Y. Mistui, K. Tanaka and S. Kusunoki: A case of anti-N-methyl-D-aspartate receptor

- encephalitis with systemic sclerosis. *European Journal of Neurology*, 18(11), E145-E146 (2011)
70. H. Barry, O. Hardiman, D. G. Healy, M. Keogan, J. Moroney, P. P. Molnar, D. R. Cotter and K. C. Murphy: Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. *Br J Psychiatry*, 199(6), 508-9 (2011)
DOI: 10.1192/bjp.bp.111.092197
71. J. Pascual-Ramirez, J. J. Munoz-Torrero, L. Bacci, S. G. Trujillo and N. Garcia-Serrano: Anesthetic management of ovarian teratoma excision associated with anti-N-methyl-D-aspartate receptor encephalitis. *Int J Gynaecol Obstet*, 115(3), 291-2 (2011)
DOI: 10.1016/j.ijgo.2011.07.028
72. P. Kashyape, E. Taylor, J. Ng, D. Krishnakumar, F. Kirkham and A. Whitney: Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients. *Eur J Paediatr Neurol*, 16(1), 74-8 (2012)
DOI: 10.1016/j.ejpn.2011.07.005
73. I. Naoura, A. Didelot, F. Walker, D. Luton and M. Koskas: Anti-N-methyl-D-aspartate receptor encephalitis complicating ovarian teratomas: a case report. *Am J Obstet Gynecol*, 205(4), e6-8 (2011)
DOI: 10.1016/j.ajog.2011.05.008
74. K. J. Frawley, M. A. Calvo-Garcia, D. A. Krueger and R. L. McMasters: 'Benign' ovarian teratoma and N-methyl-D-aspartate receptor (NMDAR) encephalitis in a child. *Pediatric Radiology*, 42(1), 120-123 (2012)
DOI: 10.1007/s00247-011-2111-6
75. H. Kawano, E. Hamaguchi, S. Kawahito, Y. M. Tsutsumi, K. Tanaka, H. Kitahata and S. Oshita: Anaesthesia for a patient with paraneoplastic limbic encephalitis with ovarian teratoma: relationship to anti-N-methyl-D-aspartate receptor antibodies. *Anaesthesia*, 66(6), 515-8 (2011)
DOI: 10.1111/j.1365-2044.2011.06707.x
76. A. Uchino, T. Iizuka, Y. Urano, M. Arai, A. Hara, J. Hamada, R. Hirose, J. Dalmau and H. Mochizuki: Pseudo-piano playing motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis: response to prompt tumor removal and immunotherapy. *Intern Med*, 50(6), 627-30 (2011)
DOI: 10.2169/internalmedicine.50.4764
77. H. Alexopoulos, M. L. Kosmidis, J. Dalmau and M. C. Dalakas: Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. *Journal of Neurology*, 258(8), 1568-1570 (2011)
DOI: 10.1007/s00415-011-5982-4
78. E. S. Frechette, L. Zhou, S. L. Galetta, L. Chen and J. Dalmau: Prolonged Follow-up and CSF Antibody Titers in a Patient With Anti-NMDA Receptor Encephalitis. *Neurology*, 76(7), S64-S66 (2011)
79. J. J. Millichap, J. L. Goldstein, L. C. Laux, D. R. Nordli, Jr., C. V. Stack and M. S. Wainwright: Ictal asystole and anti-N-methyl-D-aspartate receptor antibody encephalitis. *Pediatrics*, 127(3), e781-6 (2011)
DOI: 10.1542/peds.2010-2080
80. G. S. Day, S. M. High, B. Cot and D. F. Tang-Wai: Anti-NMDA-receptor encephalitis: case report and literature review of an under-recognized condition. *J Gen Intern Med*, 26(7), 811-6 (2011)
DOI: 10.1007/s11606-011-1641-9
81. M. Hara, A. Morita, S. Kamei, M. Yamaguchi, T. Homma, N. Nemoto, K. Sugita, T. Yamamoto and J. Dalmau: Anti-N-methyl-D-aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus. *J Neurol*, 258(7), 1351-3 (2011)
DOI: 10.1007/s00415-011-5917-0
82. M. P. Kirkpatrick, C. D. Clarke, H. H. Sonmez Turk and B. Abou-Khalil: Rhythmic delta activity represents a form of nonconvulsive status epilepticus in anti-NMDA receptor antibody encephalitis. *Epilepsy Behav*, 20(2), 392-4 (2011)
DOI: 10.1016/j.yebeh.2010.11.020
83. N. Tachibana, T. Shirakawa, K. Ishii, Y. Takahashi, K. Tanaka, K. Arima, T. Yoshida and S. Ikeda: Expression of Various Glutamate Receptors Including N-Methyl-D-Aspartate Receptor (NMDAR) in an Ovarian Teratoma Removed from a Young Woman with Anti-NMDAR Encephalitis. *Internal Medicine*, 49(19), 2167-2173 (2010)
DOI: 10.2169/internalmedicine.49.4069
84. S. H. S. Chan, V. C. N. Wong, C. W. Fung, R. C. Dale and A. Vincent: Anti-NMDA Receptor Encephalitis With Atypical Brain Changes on MRI. *Pediatric Neurology*, 43(4),

- 274-278 (2010)
DOI: 10.1016/j.pediatrneurol.2010.05.004
85. A. P. Leshner, T. J. Myers, F. Tecklenburg and C. J. Streck: Anti-N-methyl-D-aspartate receptor encephalitis associated with an ovarian teratoma in an adolescent female. *Journal of Pediatric Surgery*, 45(7), 1550-1553 (2010)
DOI: 10.1016/j.jpedsurg.2010.04.002
86. M. A. Kumar, A. Jain, V. E. Dechant, T. Saito, T. Rafael, H. Aizawa, K. C. Dysart, T. Katayama, Y. Ito, N. Araki, T. Abe, R. Balice-Gordon and J. Dalmau: Anti-N-methyl-D-aspartate Receptor Encephalitis During Pregnancy. *Archives of Neurology*, 67(7), 884-887 (2010)
DOI: 10.1001/archneurol.2010.133
87. T. Iizuka, S. Yoshii, S. Kan, J. Hamada, J. Dalmau, F. Sakai and H. Mochizuki: Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. *J Neurol*, 257(10), 1686-91 (2010)
DOI: 10.1007/s00415-010-5604-6
88. E. H. Breese, J. Dalmau, V. A. Lennon, M. Apiwattanakul and D. K. Sokol: Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Early Treatment is Beneficial. *Pediatric Neurology*, 42(3), 213-214 (2010)
DOI: 10.1016/j.pediatrneurol.2009.10.003
89. C. Bayreuther, V. Bourg, J. Dellamonica, M. Borg, G. Bernardin and P. Thomas: Complex partial status epilepticus revealing anti-NMDA receptor encephalitis. *Epileptic Disord*, 11(3), 261-5 (2009)
90. A. Labate, S. R. Irani, A. Vincent, A. Gambardella, E. Le Piane, V. Cianci and U. Aguglia: Anti-NMDA receptor encephalitis: a video case report. *Epileptic Disorders*, 11(3), 267-269 (2009)
91. A. R. De Nayer, N. Myant and C. J. Sindic: A subacute behavioral disorder in a female adolescent. Autoimmune anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Biol Psychiatry*, 66(6), e13-4 (2009)
DOI: 10.1016/j.biopsych.2009.04.031
92. A. Shindo, K. Kagawa, Y. Ii, R. Sasaki, Y. Kokubo and S. Kuzuhara: Anti-N-Methyl-D-Aspartate Receptor-Related Grave but Reversible Encephalitis with Ovarian Teratoma in 2 Japanese Women Presenting with Excellent Recovery without Tumor Resection. *European Neurology*, 61(1), 50-51 (2009)
DOI: 10.1159/000175122
93. M. Seki, S. Suzuki, T. Iizuka, T. Shimizu, Y. Nihei, N. Suzuki and J. Dalmau: Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. *Journal of Neurology Neurosurgery and Psychiatry*, 79(3), 324-326 (2008)
DOI: 10.1136/jnnp.2007.136473

Key Words: Anti-NMDA Receptor Encephalitis, Treatment, Efficacy Rate

Send correspondence to: Hsiuying Wang, Institute of Statistics, National Chiao Tung University, Hsinchu 30010, Taiwan; Tel: 886-3-5712121 ext. 56813; Fax: 886-3-5728745; E-mail: wang@stat.nctu.edu.tw